v3.26.1
Contingent Earnout Liability (Tables)
 6 Months Ended
Jun. 30, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value Measurement Inputs and Valuation Techniques Assumptions used in the valuation are described below:
June 30,
2026		December 31,
2025
Current stock price$4.55$6.98
Expected share price volatility75.0%70.0%
Risk-free interest rate4.1%3.5%
Expected term (years)2.12.6
Estimated dividend yield—%—%
The key inputs used in the valuation of the Initial OrbiMed Warrant were as follows:
June 30,
2026		December 31,
2025
Expected term (years)4.85.3
Risk free interest rate4.2%3.8%
Expected volatility75.0%70.0%
Dividend yield—%—%
Exercise price$8.1604$8.8398
Stock price$4.55$6.98
The key inputs used in the valuation of the Subsequent OrbiMed Warrant were as follows:
June 30,
2026		December 31,
2025
Expected term (years)5.66.1
Risk free interest rate4.2%3.9%
Expected volatility75.0%70.0%
Dividend yield—%—%
Exercise price$5.1556$5.3322
Stock price$4.55$6.98